Bio-Connect

anti-CD18 / LFA1 beta antibody [MEM-48] (APC)

Research Use Only
ARG53778
Arigo Biolaboratories
ApplicationsFlow Cytometry
Product group Antibodies
TargetITGB2
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Arigo Biolaboratories
  • Product Name
    anti-CD18 / LFA1 beta antibody [MEM-48] (APC)
  • Delivery Days Customer
    23
  • Applications
    Flow Cytometry
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    MEM-48
  • Conjugate
    APC (Allophycocyanin)
  • Gene ID3689
  • Target name
    ITGB2
  • Target description
    integrin subunit beta 2
  • Target synonyms
    CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; integrin beta chain, beta 2; integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); LAD; LCAMB; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; LFA-1; MAC-1; MF17; MFI7; truncated integrin beta-2
  • Host
    Mouse
  • Isotype
    IgG1
  • Scientific Description
    CD18, integrin beta2 subunit, forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1; severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis.
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203